Effects and Feasibility of Photobiomodulation at 830nm Nanometers in the Treatment of Diabetic Ulcers

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFederal University of Piaui

About this trial

Diabetic foot ulcers (DFU) are among the late complications of DFU, defined as skin lesions that involve the dermis to deeper structures, such as muscles and bones. Although preclinical studies have demonstrated the effects of GaAs 830 nm in diabetic wounds, no clinical studies have been performed, revealing the need for more in-depth analyses to identify the effects and ideal parameterization of PBM with GaAs 830 nm wavelength in the treatment of diabetic ulcers, improving quality of life, as well as to understand the therapeutic feasibility, time required for healing and recurrence rates of these lesions. Experimental, randomized, controlled, double-blind study, with blinding applied to the evaluator and participants. A total of 136 volunteers will be recruited for the research, carried out at the Integrated Center of Medical Specialties (CIEM) - Polyclinic. LLLT GaAs 830nm will be used with three dosages of low, medium and high intensity (4 J/cm², 8 J/cm², 12 J/cm²). The study will have three intervention groups using LLLT with GaAs 830nm and a control group, in which LLLLT will be performed with a GaAs 904nm wavelength and a dose of 10 J/cm², according to Saura et al (2024). This study was approved by the local Research Ethics Committee (Opinion 7,488,044), conducted in accordance with the Declaration of Helsinki and in accordance with the CONSORT (Consolidated Standards of Reporting Trials) guidelines.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Volunteers of both sexes

Age over 18 years

Medical diagnosis of diabetes mellitus (DM)

Presence of diabetic ulcer

Disqualifiers

Autoimmune diseases

Infected diabetic ulcers

Osteomyelitis

Ischemia

Trial design

Design model

Factorial

Treatments tested in this trial

  • Low Level Laser Therapy

    Device

    Painless, non-invasive treatment

Treatment groups

136 Participants
are divided into 4 treatment groups
Group A: CG + conventional dressingActive comparator 1 intervention
Group B: GL1 4J/cm2 +conventional dressingExperimental treatment 1 intervention
Group C: GL2 8J/cm2 +conventional dressingExperimental treatment 1 intervention
Group D: GL1 12J/cm2 +conventional dressingExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Ulcer area reduction rate

The ulcers will be measured with a paper ruler and photographed for later analysis of the images using the ImageJ program. The paper ruler will be positioned to measure the length and width of the ulcers.

Time frame
Pre-intervention, five weeks and ten weeks of treatment

Secondary outcomes

1

University of Texas Rankings

For analysis of ulcer depth, volunteers will be grouped into A1 and C1 (superficial ulcers), A2 and C2 (ulcers involving tendon or joint capsule) and A3 (ulcers involving bone).

Time frame
Pre-intervention, five weeks and ten weeks of treatment
2

Quality of life assessment

The EQ-5D tool will be used, consisting of five questions that assess the following aspects: mobility, personal care, usual activities, pain or discomfort, and anxiety/depression.

Time frame
Pre-intervention, five weeks and ten weeks of treatment
3

Glycemic level assessment

Volunteers' blood glucose levels will be checked once a week throughout treatment.

Time frame
Once a week for ten weeks (20 sessions)
4

Analysis of healing time and recurrence rate

Healing time:Difference, in days, between the date of the first clinical record of the lesion and the date on which the wound is considered fully healed, characterized by complete epithelialization, absence of secretion and necrotic tissue.Recurrence: assessed based on the difference, in days, between the date of complete healing and the record of recurrence of the lesion in the same region, major amputation, death or the end of the study period.

Time frame
Quarterly follow-up (3 months) after initial healing

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: